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Abstract
Rubinstein–Taybi syndrome (RSTS) is a rare malformation disorder caused by mutations in the closely related CREBBP and EP300 genes,
accounting respectively for up to 60 and 3% of cases. About 10% of CREBBP mutations are whole gene deletions often extending into flanking
regions. Using FISH and microsatellite analyses as a first step in the CREBBP mutation screening of 42 Italian RSTS patients, we identified six
deletions, three of which were in a mosaic condition that has not been previously reported in RSTS. The use of region-specific BAC clones and
small CREBBP probes allowed us to assess the extent of all of the deletions by mapping their endpoints to genomic intervals of 5–10 kb. Four of
our five intragenic breakpoints cluster at the 5′ end of CREBBP, where there is a peak of breakpoints underlying rearrangements in RSTS patients
and tumors. The search for genomic motifs did not reveal any low-copy repeats (LCRs) or any greater density of repetitive sequences. In contrast,
the percentage of interspersed repetitive elements (mainly Alu and LINEs in the CREBBP exon 2 region) is significantly higher than that in the
entire gene or the average in the genome, thus suggesting that this characteristic may be involved in the region’s vulnerability to breaking and
nonhomologous pairing. The FISH analysis extended to the EP300 genomic region did not reveal any deletions. The clinical presentation was
typical in all cases, but more severe in the three patients carrying constitutional deletions, raising a question about the possible underdiagnosis of a
few cases of mild RSTS.
© 2007 Elsevier Inc. All rights reserved.Keywords: Rubinstein–Taybi syndrome; Microdeletion; Mosaicism; Breakpoint mappingRubinstein–Taybi syndrome (RSTS; MIM 180849) is an
autosomal dominant disease that occurs in 1 of 125,000 births
and is characterized by growth and psychomotor development
delay, broad and duplicated distal phalanges of thumbs and⁎ Corresponding author. Fax: +39 2 50323026.
E-mail address: lidia.larizza@unimi.it (L. Larizza).
0888-7543/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2007.07.012halluces, typical facial dysmorphisms, and an increased risk of
tumors [1].
The etiology of RSTS was first revealed by the presence of
cytogenetic anomalies detected in a few patients, all involving
chromosome band 16p13.3 [2–4]. Subsequent fluorescence in
situ hybridization (FISH) studies using a panel of probes
encompassing 16p13.3 showed that most patients carry
microdeletions involving the CREB-binding protein gene,
CREBBP, commonly referred to by its shorter acronym CBP
568 C. Gervasini et al. / Genomics 90 (2007) 567–573(MIM 600140) [5–7], which paved the way to the targeted
screening of CBP.
Alterations in the CREBBP gene, including heterozygous
point mutations and deletions, have been identified in 56–61%
of RSTS patients [6,8–10], with deletions representing about
10% of the lesions. All of the N60 CREBBP microdeletions so
far reported were de novo and, when parental origin could be
investigated, no preferential maternal or paternal contribution of
the affected chromosome 16 was observed. Various techniques
have been applied, including FISH [7,11], real-time quantitative
PCR [12], and multiplex ligation-dependent probe amplifica-
tion, which refined mainly the point mutation repertoire by
adding small intragenic deletions [13].
When the deletion breakpoints were defined by FISH
mapping, a great variety of deletion ends was observed,
including breakpoints inside or outside the CREBBP gene or
one break inside and the other jutting beyond the 3′ or 5′ end
[7,11,12]. No genomic motifs were revealed that might prime
nonallelic homologous recombination (NAHR) recurrent dele-
tions associated with a more severe CREBBP-related phenotype
than that due to inactivating point mutations. With a few
exceptions [11], clinical features are slightly more severe in
patients with deletions [14], thus making it unlikely to define an
RSTS contiguous gene syndrome characterized by a specific
phenotypic spectrum, as shown by most CREBBP microdeleted
patients.
No CREBBP mosaic deletions have yet been reported,
although numerous somatic rearrangements (mainly transloca-
tions disrupting CREBBP) have been described in M4/M5
subtypes of acute myelogenous leukemia [6,15–21]. Both
germ-line and somatic rearrangements affecting CREBBP seem
to determine the loss or impairment of the multifunctional
CREBBP protein, although the rearrangement leads to a
chimeric gene as in leukemias.
During a search for other genes whose disruption might
account for CREBBP-negative RSTS, a small subset (3%) of
the tested patients was found to carry mutations in the
CREBBP-related EP300 gene [22]. Refined evaluation of the
clinical presentation of the three identified EP300-mutated
patients (and an additional case) revealed much milder hand and
feet skeletal findings than those typically observed in CREBBP-
mutated RSTS patients [23]. No EP300 deletions have yet been
reported in RSTS patients with a classic or mild phenotype.
We here describe six CREBBP microdeletions identified in
Italian RSTS patients screened for CREBBP point mutations in
parallel or previously [9]. FISH with BACs and small BAC-
derived probes allowed the precise mapping of the 12 under-
lying breakpoints to 11 different genomic intervals, thus
providing a detailed genomic view of nonrecurrent CREBBP
deletions. Interestingly, three of the six deletions were in a
mosaic condition, a novel finding in microdeleted RSTS
patients. Despite the small number of deleted cells in the
investigated tissues, the clinical phenotype was quite typical,
thus emphasizing the dose sensitivity of CREBBP. We also
sought EP300 deletions in the CREBBP-negative patients and
confirm the limited role of the second highly homologous gene
in the etiology of RSTS.Results
We report the genomic characterization of six deletions
affecting the CREBBP gene and flanking regions, which were
identified in a cohort of 42 Italian RSTS patients who
underwent FISH screening as a first step in CREBBP mutation
testing. The recruited patients then entered the CREBBP point
mutation scan, which led to the confirmation or exclusion of
CREBBP involvement, as previously described [9].
By genotyping the polymorphic intragenic repeats MS4,
MS2, and D16S3065 (plus one SNP), we identified two
deletions encompassing all or almost all of the CREBBP gene in
two patients, respectively (patients 30 and 41) (Fig. 1), and
FISH analysis using region-specific BAC clones and small
CREBBP probes allowed us to assess the extent and
approximate boundaries of both deletions. The deletion of
patient 30 encompasses a 150-kb region between CREBBP
exons 2 and 31, and that of patient 41 (about 500 kb in size)
extends beyond the 5′ and 3′ ends of the gene (Fig. 1). A third
deletion encompassing the whole CREBBP gene with very
large (2.6 Mb) involvement beyond the 5′ end was identified in
patient 82 by FISH analysis. All three deletions affect the
maternal allele, as assessed by segregation analyses of region-
specific microsatellites (data not shown).
FISH analysis also enabled the detection of three additional
deletions, all in the mosaic condition (Figs. 1 and 2): two affect
the 5′ end of the gene, with a span of 335 kb in patient 40 and
275 kb in patient 66; the third, which includes a significant
portion of the gene, extends for 720 kb to the 3′ flanking region
(patient 38) (Fig. 1). In all cases, the lymphocytes contained
≤30% deleted cells (Fig. 2). In the case of two patients (40 and
66), FISH analyses were also made of buccal smears, which
allowed the scoring of almost 100 nuclei. The average
percentage of deleted cells in the epithelial cell lineage was
less (20%) than in the circulating lymphocytes (Fig. 2), thus
confirming low-level mosaicism. The size of the identified
deletions varied widely from 150 kb (patient 30) to 2.6 Mb
(patient 82) (Fig. 1). FISH experiments using locus-specific
probes allowed us to delimit the region breakpoints to genomic
intervals of 5–10 kb. All 12 breakpoints are private, except for
the telomeric breakpoints of patients 41 and 82, whichmap to the
same interval. Three breakpoints are located in a 500-kb region
telomeric toCREBBP, 4 are in a 2.2-Mb region centromeric to it,
and 5 are embedded in the CREBBP gene (Fig. 1). Of the 5
intragenic breakpoints 4 (3 involved in the mosaic deletions)
cluster to a small interval around exon 2 at the 5′ end of the gene.
We reviewed the literature concerning the CREBBPmapping
of breakpoints underlying germ-line deletions and balanced
rearrangements in RSTS patients, as well as somatic rearrange-
ments (mainly translocations involved in tumors). Supplemental
Fig. 1 shows a magnification of the genomic structure of
CREBBP with an overview of the germ-line (top) and somatic
breakpoints (middle), all of which are listed and referenced in
Supplementary Table 1. The internal CREBBP breakpoints
shown in Supplemental Fig. 1 constitute about half of the
reported deletion breakpoints with defined boundaries
[7,11,12]. The predominant mapping of breakpoints to the
Fig. 2. Representative FISH results relating to the patients carrying CREBBP
mosaic deletions. (Top) Table showing the percentages of deleted cells from
lymphocytes and buccal cells, where available. (Bottom) FISH experiments on
lymphocyte metaphases from patient 66 (a, b) and buccal cell nuclei from patient
66 (c) using BAC clone RP11-534j13 and reference subtelomeric 16q probe
BAC clone RP11-566K11. The arrows point to the deleted chromosome 16 and
nucleus.
Fig. 1. Mapping of six CREBBP deletions to the CREBBP genomic region. (Top) Reference map of UCSC Web site (www.genome.ucsc.edu) with known genes
(in black) and CREBBP underlined. The base distances from tel to cen are indicated left to right. The BAC clones used in the FISH experiments are represented by
gray bars aligned under the map. The small gray boxes below the bars indicate the locus-specific probes generated by the BACs and used to narrow the breakpoint
FISH mapping. (Bottom) Schematic diagram of the deletions represented by bars aligned below the physical map. The bars are black for the three constitutional
deletions (top down by decreasing size) and filled with diagonal lines for the mosaic deletions (top down by decreasing size). The dashed vertical lines indicate the
deletion breakpoints. The size of each deletion is shown on the left, and the patient code on the right.
569C. Gervasini et al. / Genomics 90 (2007) 567–573CREBBP portion around exon 2 extended bidirectionally to
IVS1 and IVS2 (enframed in all of the panels of Supplemental
Fig. 1) is observed in meiotic rearrangements, whereas there is
an almost exclusive clustering of mitotic breakpoints in this
critical area [15,17,19,20].
We performed an in silico analysis of the sequence of the
delimited region searching for specific DNA sequence motifs
(palindromic elements, recombination-specific sites, LCRs)
that might be associated with the rearrangements, but none was
detected. Conversely, the breakpoint cluster region around
exon 2 was marked by a crowding of repetitive elements,
SINEs, LINEs, LTRs, and DNA elements of the Mer type. In
particular, the percentage of LINEs (20%) was significantly
higher than their percentage in the entire gene (8%) and
contributed mainly to the overall increase in interspersed
sequences in the critical region (56% vs 35% in the entire
CREBBP) (Supplemental Fig. 1, bottom).
Table 1 summarizes the major and minor clinical signs of the
six patients carrying constitutional or mosaic microdeletions,
indicating the size, extent, and gene content of the deletion.
Regardless of their specific microdeletion and its constitu-
tional or mosaic occurrence, all of the patients are affected by
psychomotor delay and mental retardation and show the typical
sign of broad thumbs or great toes. The clinical presentation of
the three patients carrying whole gene deletions (patients 30, 41,
Table 1
Germ-line deletions Patient No.
82 41 30
Size 2.6 Mb 500 kb 150 kb
Involved genes (tel–cen order) ZNF434, ZNF174, ZNF597, BTBD12,
DNASE1, TRAP1, CREBBP, ADCY9,
TFAP4, GLIS2, CORO7, VASN,
DNAJA3, HMOX, UBN1, PPL,
NAGPA, ALG1, A2BP1
ZNF434, ZNF174,
ZNF597, BTBD12,
DNASE1, TRAP1,
CREBBP, ADCY9
CREBBP
Patient gender/age at diagnosis F/1 day F/25 years F/29 years
Facial dysmorphisms
At birth Prominent beaked nose,
columella below the alae nasi,
downslanting palpebral fissures,
micrognathia
− +
At diagnosis Downslanting palpebral
fissures, columella below
the alae nasi
Low junction of hair,
prominent beaked nose,
columella below the alae
nasi, micrognathia
Development
Mental retardation NA + +
Failure to thrive + + +
Feeding difficulty in infancy + − +
PM delay + + +
Microcephaly − + +
Skeletal anomalies
Broad thumbs or big toes + + +
Other Highly arched palate Scoliosis Clinodactyly
Other Hypertricosis, forehead
hemangioma, laringeal
synechia, hypotonia
Forehead hemangioma,
myopia/strabism, obesity
Myopia/strabism,
obesity, sebacee cysts
Mosaic deletions 38 40 66
Size 720 kb 335 kb 275 kb
Involved genes (tel–cen order) ZNF205, ZNF213, ZNF200,
ZNF263, MEFV, TIGD7,
ZNF434, ZNF174, ZNF597,
BTBD12, DNASE1, TRAP1,
CREBBP
CREBBP, ADCY9,
TFAP4, GLIS2,
CORO7, VASN,
DNAJA3
CREBBP, ADCY9
Patient gender/age at diagnosis M/5 years F/24 years M/6 years
Facial dysmorphisms
At birth − − −
At diagnosis Prominent beaked nose Low junction of hair Prominent beaked nose,
micrognathia, columella
below the alae nasi
Development
Mental retardation + + +
Failure to thrive − + +
Feeding difficulty in infancy + − −
PM delay + + +
Microcephaly − + −
Skeletal anomalies
Broad thumbs or big toes + + +
Other Clinodactyly, scoliosis Highly arched palate,
clinodactyly
Other Hypertricosis,
disturbance of sleep
Myopia/strabism,
hypotonia
Kidney abnormality
All patients have normal karyotype, except for patient 38: 46,XY,der(14)t(9;14)(p11.2;p11.2). NA, not applicable.
570 C. Gervasini et al. / Genomics 90 (2007) 567–573and 82) is generally more severe than that of the carriers of
mosaic deletions (40, 66, and 38). There was no clear
relationship between the size of the deletion and the manifesta-
tion of uncommon or atypical RSTS signs, thus making it
difficult to attribute these signs to the haploinsufficiency of
specific genes.To establish whether deletion-type mutations might affect the
CREBBP-related EP300 gene, 33 patients who were negative
for CREBBP microdeletions were tested for EP300 microdele-
tions using the specific RP11-1078o11 BAC clone. None of
these cases lacked the EP300-specific FISH signal (data not
shown).
571C. Gervasini et al. / Genomics 90 (2007) 567–573Discussion
We carried out a refined FISH characterization of the extent
and boundaries of six CREBBP microdeletions identified in a
cohort of 42 Italian subjects with a clinical diagnosis of RSTS.
Possibly due to the mosaic occurrence of three deletions, our
deletion rate is higher (14%) than that usually reported (10%).
The identified deletions vary widely in size and position,
with only two breakpoints mapping to the same 15-kb interval,
and comparison with other CREBBP deletions characterized in
the literature confirmed the paucity of shared underlying
breakpoints [7,11,12]. As breakpoint mapping has been refined
on less than half of the approximately 60 described cases,
comparison of the number of CREBBP deletions is informative
but may not be fully representative. However, despite this
limitation, the published background information and our
genomic characterization using FISH probes, which ensures a
resolution up to a few kilobases, concur in excluding a main
recurrent deletion in RSTS. Consistent with this evidence in
silico studies of the sequence environment of CREBBP and its
flanking regions showed the lack of any LCR flanked by
repetitive or palindromic sequences that might prime NAHR,
leading to recurrent deletions. Indeed the overall deletion
frequency for the CREBBP gene (10%) is similar to that of the
neurofibromatosis type 1 gene [24,25], in which LCR-mediated
deletions lead to the recurrent NF1 microdeletion syndrome
[26–31]. The described CREBBP-deleted patients do not
associate with a RSTS microdeletion syndrome. The feature
of scattered breaks clearly emerges from the analysis of the
RSTS deletions described by us and those in the literature that
have undergone breakpoint mapping [7,11,12]. Further char-
acterization of the breakpoints up to the sequence of junction
fragments may even differentiate apparently similar breakpoints
by expanding their scattering across a critical unstable region.
Only one study has so far defined the sequence junctions of two
CREBBP partial deletions (exons 14–16 and exons 4–26) [13],
and this added further evidence of the CREBBP genomic
region’s susceptibility to breakage.
Inspection of the somatic events involving CREBBP [17,19]
has not revealed any deletions, but did reveal translocations
whose CREBBP breakpoints confirm a kind of genomic
instability characterized by scattered rather than clustered
genomic motifs.
One exception to the above, however, is the breakpoint
cluster observed in the 5′ region of the gene, as 4 of the 12
breakpoints (including 3 of mosaic deletions) are embedded in a
40-kb sequence between IVS1 and IVS2 (Fig. 2 and Supple-
mental Fig. 1). This interval includes most of the entire
CREBBP deletion, inversion and translocation breakpoints of
described RSTS patients [1,7,11–13], and most of the break-
points of the translocations interrupting the CREBBP gene in
the M4/M5 subtypes of acute myeloid leukemia [15,17,19,20]
(Supplemental Fig. 1). There is an increased percentage of
different repetitive elements (particularly SINEs and LINEs) in
this sequence in comparison with the average percentage in the
genome and the entire CREBBP gene (as has been pointed out
by Coupry et al. [10] and Panagopoulos et al. [17]), but it is thegeneral increased frequency of interspersed repetitive elements
rather than that of a single type of element that may make this
region a break “hot spot” in terms of both meiotic and mitotic
recombination.
Nevertheless, the breakpoints clustered in this hot spot are
unique and scattered, as shown by refined studies of the
translocations affecting CREBBP in leukemia [17–21,32,33].
These studies have provided evidence showing the involvement
of Alu elements and LINEs in the double-strand breaks,
possibly repaired by a nonhomologous end-joining mechanism
[17,33]. Interestingly, the involvement of Alu and Alu–LINEs
has been demonstrated for two CREBBP partial deletion
junctions [13].
Ours is the first description of a relatively high frequency of
mosaic deletions (three of six) in patients with RSTS and
suggests that mosaicism might be underestimated, as they were
all in the group of CREBBP-negative cases. The limitations of
the technique in detecting mosaic point mutations are known,
and the low level of mosaicism scored in the tested tissues can
be easily detected only by FISH analyses. Indeed mosaic patient
40, showing in two tissues an average percentage of 18.5% of
deleted cells, had been previously tested for segregation from
parents of intragenic CREBBP microsatellites, not revealing
any allele loss.
Our data allow a few comments concerning the general
issue of genotype/phenotype correlations. A first point regards
the three patients carrying mosaic deletions (patients 38, 40,
and 66), who were all referred for CREBBP screening because
they presented with a recognizable RSTS phenotype. Given the
low level of deleted cells in the tissues available for analysis,
the dose sensitivity of the CREBBP gene is clear, as a mutation
in a small portion of cells is sufficient to determine the
Rubinstein–Taybi phenotype. The overall phenotype of the
mosaic patients was less severe than that of those with
constitutional deletions (almost borderline in the case of patient
66), which emphasizes the possibility that mild RSTS cases
may be underestimated.
Second, the constitutional deletions ranged in size from
150 kb to 2.6 Mb, with the child carrying the largest deletion not
presenting an overtly severe phenotype until at least the age of 1
year. Further cases carrying a deletion covering the same
genomic region should be compared to check whether the
haploinsufficiency of 18 genes (in addition to CREBBP) is
responsible for any particular additional sign and can thus be
classified as “dose sensitive.” The severity of the phenotype of
patients with large deletions has been described by Bartsch et al.
[11], but our patients did not have similar features. Critical
infections manifesting as medical complications in patients with
deletions including the DNASE1 gene were not observed in our
completely haploinsufficient patients 82 and 41 or in our
partially haploinsufficient patient 38. Nevertheless, as sug-
gested, specific attention should be paid to the risk of critical
infections in this subgroup of deleted patients.
These considerations concerning the phenotypes of our
patients (particularly that of patient 82, carrying a 2.6-Mb
deletion) are not consistent with the definition of a microdele-
tion RSTS syndrome. The presence of genomic involvement in
572 C. Gervasini et al. / Genomics 90 (2007) 567–573a subgroup of deleted RSTS patients is unquestionable, but it is
difficult to discern a different and distinguishable phenotype
from that of patients carrying a point mutation.
Our patients who were negative for CREBBP mutations/
deletions were investigated for the putative presence of an
EP300 deletion. Roelfsema et al. [22] extended the screening
of 92 RSTS patients who were negative for CREBBP point
mutations to the EP300 gene and found three mutations
causing RSTS. This very low mutation rate [34] indicates the
minor role of EP300 in this syndrome, but the recently
reported mild phenotype of the four currently known EP300-
mutated patients [23] might be reconsidered to recruit also
RSTS group B patients (i.e., those with a borderline
phenotype) to check the mutation rate. None of our patients
tested for EP300 deletions showed a rearrangement in this
region, possibly because of the specific genomic interval and
the absence of motifs promoting genomic breaks. However, as
microdeletions usually represent a small subset of all
mutations, and only a very small number of EP300 point
mutations have so far been detected, a larger cohort of both
typical and mild/borderline RSTS patients should be tested to
exclude this kind of rearrangement.
Materials and methods
Subjects and cell lines
Peripheral blood samples were obtained from all six patients after they had
given their informed consent. A lymphoblastoid cell line was established in two
cases (30 and 41).
Clone preparation
All of the BAC clones were supplied by Mariano Rocchi (Resources
for Molecular Cytogenetics, University of Bari, Italy; http://www.biolo%
20gia.uniba.it/rmc/) and the Wellcome Trust Sanger Institute Genome
Campus (Hinxton, Cambridge, UK) or purchased from Invitrogen S.r.l. or
the Chori BAC PAC Resource Center (Oakland, CA, USA). DNA was
obtained starting from a single colony grown in 10 ml of LB medium
supplemented with 12.5 μg/ml chloramphenicol (Sigma) following standard
procedures.
Locus-specific probe preparation
The method, which has been previously described [35], is based on two
consecutive reactions using BAC clones containing the loci of interest.
Cell culture, chromosome, and interphase nucleus preparations
Phytohemagglutinin-stimulated peripheral blood lymphocytes were set up in
culture from samples using the chromosome kit “Synchro” (Celbio) and
modified RPMI (Irvine Scientific) plus 5% fetal calf serum (Gibco). The cultures
were stopped with colchicine after 72 h. The chromosome preparations were
obtained using a standard technique.
A lymphoblastoid cell line was established from the peripheral blood of
patients 30 and 41 using Epstein–Barr virus in accordance with standard
procedures by means of a service provided by the Telethon Research Service
“Galliera Genetic Bank.”
For the interphase nucleus preparations made from buccal smears of the
mosaic deletion patients, the oral cavity was rinsed twice with drinking water
and then scraped with a premoistened applicator or cytobrush. The cells were
resuspended in 1×PBS supplemented with antibiotics. After a 2000-rpm spinfor 5 min, 10 ml of hypotonic solution (0.5 M KCl) was added for 10 min. The
nuclei were then fixed in Carnoy’s solution. The samples were uniformly
smeared across a prelabeled clean slide.
FISH
BAC clones and locus-specific probes were labeled with digoxigenin–dUTP
(Roche Diagnostic) using a nick-translation kit (Roche Diagnostic). The FISH
experiments were performed using standard procedures [36]. The chromosomes
were counterstained with DAPI in antifade (Vectashield) and then visualized
using a Leitz DM-RB microscope equipped for DAPI and FITC/TRITC
epifluorescence optics. The images were captured by means of a CCD camera
(Hamamatsu 3CCD Camera, C5810) and visualized using Highfish software
(Casti Imaging).
Score of FISH signals in the mosaic condition
Almost 50 metaphases and 100 nuclei were scored for each sample to
establish the mosaic condition. Only intact and undamaged nuclei free of
cytoplasm were analyzed; nuclei with low signal intensities, diffuse signals, or
no signal on either homologue chromosome were considered hybridization
failures and not scored. Two small focal (or paired) signals of the same color and
intensity, separated by a distance of less than the area of one signal, were
considered to be a split signal from one chromosome. Interphase nuclei with one
large signal of the same color and more intense fluorescence in the absence of a
second hybridization signal were considered as representing the overlapping (or
overposition) of two signals and were not scored. Informative mosaic samples
were defined as those in which more than 5% of the nuclei had a reproducible
abnormal pattern of signals compared to the expected chromosomal signals.
Haplotype analysis
Fluorescent genotyping was performed as previously described [10]. The
fluorescent dye-labeled chromosome 16p microsatellite markers MS4, MS2, and
D16S3065 (from centromere to telomere), and the c.5454 G → A SNP, were
used for segregation analysis from parents to probands. Fluorescence was
detected using an ABI 3100 sequencer. ABI Prism software (Genescan) was
used for gel analysis.
In silico analysis
The in silico sequence analysis was made using the following databases and
tools: Entrez Nucleotides Database, http://www.ncbi.nlm.nih.gov/Entrez/query.
fcgi%3Fdb = nucleotide; MAR-Wiz, http://www.futuresoft.org/ (for searching
recombination-specific sites); NCBI BLAST, http://www.ncbi.nlm.nih.gov/
Blast/; UCSC Genome Bioinformatics, http://www.genome.ucsc.edu/ (for
sequence homology analyses and evaluation of the G+C content, the selection
of the BAC/PAC clones to be used in the FISH experiments, and the generation
of locus-specific probes); and Palindrome, http://bioweb.pasteur.fr/seqanal/
interfaces/palindrome.htlm (to search for palindromic elements).
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